The aim of the present study was to investigate whether long-term exposure to valproate (VPA) alters follicular steroidogenesis and whether or not this effect is dependent on the degree of follicular development. Small-and medium-sized follicles were obtained from pig ovaries collected, respectively, at days 8-10 and 14-16 of oestrus cycle. Theca interna and granulosa cells were isolated from follicles and placed in the same well in the ratio 1 : 3 with or without the VPA in doses of 100, 300 and 500 µg ml −1 . The culture medium was changed after 2, 4, 6 and 8 days. In both types of follicles, VPA caused a significant and dose-dependent reduction in both testosterone and estradiol secretion from follicular cells. In small-sized follicles, the testosterone to oestrogen ratio increased at all doses used and after all lengths of time in culture. In medium-sized follicles, a significant increase in the testosterone to oestrogen ratio was only observed at the highest dose level. All doses of VPA caused a marked inhibition of progesterone secretion after 48 hours while during long-term VPA exposure progesterone gradually increased demonstrating luteinization of cells. In conclusion, the present study demonstrates a direct effect of VPA on steroidogenesis. The effect seems to differ to some extent depending on the follicular stage of development. The elevated ratio of testosterone to estradiol suggests that VPA inhibits the conversion of testosterone to estradiol.
INTRODUCTION
Valproate (VPA) is a major antiepileptic drug with a broad spectrum of antiepileptic activity. It has been the drug of choice in the treatment of most forms of primary generalized epilepsies and is also efficient against partial seizures [1] [2] [3] . There is, however, increasing concern about the possible effects of antiepileptic drugs, especially VPA, on reproductive endocrine function [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . In 1981, Margraff and Dreifuss 14 were the first to report amenorrhoea as a side effect of VPA. This has later been confirmed in a series of studies from Isojärvi and coworkers [6] [7] [8] who found menstrual disorders, polycystic ovaries and/or hyperandrogenism in as many as 60% of women receiving chronic VPA treatment. These changes were partially reversible by replacing VPA with lamotrigine indicating a drug-specific effect 9 . In accordance with this, Murialdo et al. 11, 12 showed that in epilepsy patients receiving VPA as part of a polytherapy regimen, 40% developed polycystic ovaries while 63.5% of all patients on VPA had elevated serum androgen levels and hyperandrogenic anovulation. Estradiol levels were lower than in healthy controls in the follicular phase 12 .
Folliculogenesis is disturbed in patients with polycystic ovary syndrome (PCOS) 15 . The initial steps, recruitment and growth of the small Graafian stages, are functional in PCOS, but the selection of dominant follicles to be ovulated does not occur regularly. This leads to accumulation of a large number of small Graafian follicles (commonly referred to as cysts) in which the theca interstitial cells produce abnormally large amounts of androgen while the granulosa cells fail to aromatize the androgen substrate to estradiol. It has also been recently shown in non-epileptic rats that VPA induces polycystic ovaries and changes in peripheral sex steroid hormone levels, pointing to a drug-specific effect on endocrine function independent of epileptic activity 16, 17 . The question then arises whether this is a centrally mediated effect or a direct effect of the drug on folliculogenesis and steroid hormone secretion in the ovary. The aim of the present study was first to investigate the possibility of a direct effect of VPA on follicular cells and then to investigate whether this effect was dependent upon follicular development.
MATERIALS AND METHODS

Reagents
Parker medium (M199), calf serum, trypsin and PBS were obtained from Biomed, Lublin, Poland. Antibiotic antimycotic solution (1%) was obtained from Sigma Chemical Co., St Louis, MO, USA. Sodium valproate (VPA) was a gift from Desitin Pharma, Norway.
Cell cultures
Porcine ovaries obtained from a local abattoir were collected into a bottle filled with sterilized ice-cold saline and transported to the laboratory. Approximately 1.5 h elapsed from slaughter to collection in the laboratory. Small-and medium-sized follicles were obtained from ovaries collected, respectively, at days 8-10 and 14-16 of the oestrus cycle as described previously 18, 19 . Granulosa cells (Gc) and theca interna cells (Tc) were subsequently prepared.
The separation of Gc from the theca layer was performed according to the technique described by Stoklosowa et al. 20 . Gc were scraped from the follicular wall with round-tipped ophthalmologic tweezers and rinsed several times with PBS. After collection, granulosa cells were washed three times in M199 containing 100 IU ml −1 penicillin and 1 mg ml −1 nystatin, and were recovered by centrifugation (10 min at 200 g). The theca cells from the same follicles were prepared as previously described in detail by Stoklosowa et al. 20 . Briefly, the theca layers were placed in a drop of saline under the dissection microscope. The theca interna was manually separated from the underlying theca externa. The isolated theca interna tissue was then washed, cleaned, cut with scissors and trypsinated with 6-7 ml 0.25% trypsin in PBS for 10 min at 37 • C. The cells were separated by decanting. This procedure was repeated three times.
The cell viability, determined using the trypan blue exclusion test, was 85% for theca cells and 92% for granulosa cells. The average yield of granulosa cells was 5.0 × 10 5 cells ml −1 for small-sized follicles and 0.7 × 10 6 cells ml −1 for medium-sized follicles.
In co-culture experiments, 1 ml each of suspended Gc and Tc cells were placed in the same well giving a total of 2 ml of culture medium per well. Thecaderived androgens served as a substrate for production of estradiol by Tc cells in co-culture with Gc. The cultures were maintained at 37 • C in a humidified atmosphere of 5% CO 2 /95% O 2 . Cells were cultured in Parker Medium (M199) supplemented with 10% calf serum with or without added VPA in doses of 100, 300 and 500 µg ml −1 . The culture medium was changed after 48, 96, 144 and 192 hours and the collected media were stored at −20 • C until steroid analysis. Every treatment was conducted in five wells and each experiment was repeated three times.
Steroid analysis
Testosterone (T), 17β-estradiol (E2) and progesterone (P4) levels were determined by radioimmunology using Spectra kits (Orion, Diagnostica, Finland), supplied by Polatom (wierk, Poland).
For testosterone, the limit of the assay sensitivity was 5 pg ml −1 . The coefficients of variation within and between assays were 5.4% and 5.3%, respectively. The mean recoveries were 84.2-121.7%. The crossreaction with 5α-dihydrotestosterone was 4.5%. All other tested steroids (methyltestosterone, androstendione, progesterone, 17β-estradiol) showed less than 0.5% cross-reaction.
For 17β-estradiol, the detection limit of assay was 5 pg. The coefficients of variation between and within assays were 10.28% and 2.9%, respectively. The mean recoveries were 85.6-108.9%. The cross-reaction with ethinylestradiol was 1.4%. All other tested steroids (estrone, estriol, progesterone, testosterone, corticosterone) showed less than 1% cross-reaction.
For progesterone, the assay sensitivity was 94 pg ml −1 . The coefficients of variation between and within assays were 5.8% and 2.9%, respectively. The mean recoveries were 95.1-103.7%. The cross-reaction with pregnenolone was 2.9%. All other tested steroids (5β-dihydroprogesterone, 20β-hydroxyprogesterone, corticosterone, testosterone, estrone) showed less than 1% cross-reaction.
Statistical analysis
All data points are expressed as means ± SEM from at least three different experiments (n = 3), each in quintuple. The significance of differences between the concentrations of progesterone, estradiol and testosterone in the control and experimental cultures were compared by analysis of variance and by Duncan's new multiple range test. 
RESULTS
Small follicles
In the control culture, follicular cells secreted 26.1, 36.5, 37.3 and 37.9 ng ml −1 of testosterone, respectively, after 2, 4, 6 and 8 days. The amount of estradiol secreted into the culture medium did not change during the study and was approximately 10 ng ml −1 ( Fig. 1(a)-(d) ). The ratio of testosterone to oestrogen in the control culture was 2.6 after 2 days of culture and then 3.4 after 4, 6 and 8 days of culture. VPA added to the culture medium caused a significant and dose-dependent reduction in both testosterone and estradiol secretion from follicular cells. The ratio of testosterone to oestrogen increased depending on the doses used and the length of time in culture. After 2 days of culture with VPA, the testosterone to oestrogen ratio was 3.1, 4.6 and 5.5, respectively, for 100, 300 and 500 µg VPA ml −1 medium. This change towards an increased testosterone to oestrogen ratio was observed after all lengths of culture ( Fig. 1(a)-(d) ).
Exposure to all doses of VPA caused a marked inhibition of progesterone secretion after 2 days ( Fig. 1(a) ). However, during long-term VPA exposure progesterone gradually increased demonstrating luteinization of cells. Compared to the progesterone level at day 2, the progesterone levels at days 4, 6 and 8 increased by a factor of 1.4, 1.6 and 1.8, respectively, in control cells not exposed to VPA. Corresponding values for VPA-treated cells were 6.6, 8.0 and 8.9 using a dose of 100 µg ml −1 ; 7.0, 10 and 10.7 after a dose of 300 µg ml −1 and 3.5, 4.9 and 4.9 after a dose of 500 µg ml −1 .
Medium follicles
In the control culture, follicular cells secreted 26.4, 30.1, 33.2 and 33.5 ng ml −1 of testosterone, respectively, after 2, 4, 6 and 8 days. A higher amount of estradiol secreted by this type of follicle was observed (42.9, 46.3, 46.7 and 47.2 ng ml −1 , respectively, after 2, 4, 6 and 8 days of culture) (Fig. 2(a)-(d) ). The ratio of testosterone to oestrogen in the control culture was 0.67 and did not change during the study. VPA in a dose of 100 µg ml −1 did not change the testosterone to oestrogen ratio. After a dose of 300 µg ml −1 the ratio of testosterone to oestrogen was 1 during all days of culture, while after a dose of 500 µg ml −1 the ratios were 1.6, 1.8, 2 and 2.7, respectively, after 2, 4, 6 and 8 days of culture. VPA inhibited progesterone secretion compared to control at all doses used and at all investigated days of culture. As in the small follicles, luteinization was observed during long-term exposure in both control cells and VPA-treated cells by steadily increasing progesterone levels. In the control culture, progesterone increased by a factor of 1.42, 1.6 and 1.9, respectively, at days 4, 6 and 8 compared to the progesterone level at day 2. In VPA-treated cells, progesterone increased by a factor of 2.0, 2.4 and 3.0 after 100 µg ml −1 ; 1.8, 1.9 and 2.6 after 300 µg ml −1 and 1.8, 2.3 and 2.8 after 500 µg ml −1 , respectively, at days 4, 6 and 8 compared to the progesterone level at day 2.
DISCUSSION
The presented data clearly show that VPA has a direct effect on follicular steroidogenesis. In small follicles, which produce small amounts of estradiol and have low P450 aromatase activity, VPA decreased both testosterone and estradiol secretion while the ratio of testosterone to oestrogen increased. In medium-sized follicles with a higher aromatization capacity, the ratio of testosterone to oestrogen also increased after a VPA concentration of 500 µg ml −1 , changing the ratio towards testosterone secretion.
Our data, showing a direct effect of VPA on testosterone secretion from follicular cells, are supported by observations of Elias et al. 21 , Melis et al. 22 , Lado Abeal et al. 23 and Isojärvi et al. 6, 7 which show that women receiving VPA had normal serum LH levels with normal LH responses to GnRH. The effect of VPA on ovarian endocrine function can thus be explained by a direct effect upon the ovary, although an additional, centrally mediated effect cannot be totally excluded.
Tamura et al. 24 demonstrated that the granulosa cells of PCOS follicles were mainly negative for P450 aromatase which would reduce the conversion of testosterone to oestrogen. In accord with this, Isöjarvi et al. 6 showed that serum estradiol concentrations were not elevated in VPA-treated women despite elevated serum testosterone concentrations, suggesting that VPA inhibited the conversion of testosterone to estradiol. This gains further support from the observations of lower estradiol levels in VPA-treated women vs. healthy controls studied in the follicular phase 12 . Elevation of the testosterone to estradiol ratio, as demonstrated in our study, suggests that VPA inhibits the conversion of testosterone to estradiol. The most likely explanation for this finding is thus an inhibition of P450 aromatase activity by VPA treatment.
In a study of endocrine effects of chronic VPA treatment in rats, Taubøll et al. 16 showed a significantly increased number of follicular cysts together with reduced testosterone and a trend towards reduced oestrogen levels after 3 months. The testosterone to oestrogen ratio was unchanged between controls and animals receiving either 50 or 200 mg kg −1 day −1 of VPA. Serum VPA concentrations were 72 and 200 µmol l −1 in the two treatment groups which are actually below therapeutic range in humans. In a similar long-term study using higher VPA doses of 400 and 600 mg kg −1 day −1 with serum concentrations well within therapeutic range, the same group demonstrated a marked increase in the testosterone to oestrogen ratio in accordance with our findings 25 . It may thus be that the effect of VPA on P450 aromatase activity is more pronounced at higher serum concentrations. In the present study, the VPA concentrations used ranged from the therapeutic range (100 µg ml −1 ) and upwards. However, it must be kept in mind that the so-called therapeutic range in humans represents minimum concentrations as trough morning levels. It is well known that due to the kinetics of the drug, diurnal fluctuations in the range of several hundred percent occur also in humans 26, 27 . Further, the effects of VPA on the secretion of hormones from follicular cells in our study was, except for a degree of magnitude, independent of VPA concentrations and still significant at the lowest concentration used, which was within the therapeutic range for humans. We therefore consider our findings of clinical relevance for chronic VPA treatment in epilepsy patients.
The presented data clearly showed decreased progesterone secretion after short-term VPA treatment. Although data on progesterone production from follicular cells in women with PCOS is limited, our finding gains some support from the study of Erickson et al. 15 which demonstrated reduced progesterone production from granulosa cells in women with PCOS. Reduced progesterone secretion was also observed in follicular cells from women with PCOS following gonadotropin hyperstimulation 28 . On the other hand, Gilling-Smith et al. 29 and Willis et al. 30 suggested increased basal progesterone levels in anovulatory PCOS. This increase in basal progesterone levels has been suggested to be due to an abnormal regulation of P450c17α function which may explain the hyperandrogenic function 31 .
In conclusion, the present study suggests a direct effect of VPA on ovarian endocrine function. Our data thus support previous findings in humans [6] [7] [8] [9] and recent studies in non-epileptic rats 16, 17, 25 showing changes in ovarian morphology and endocrinology after chronic VPA treatment.
